First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients
Authors:
- 27 November 2020
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 62 (7) , 975-978
Abstract
Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as olaparib, might be used to overcome the limitations of radioligand therapy (RLT) with 177Lu-prostate-specific membrane antigen (PSMA) in metastasized castration-resistant prostate cancer. Here, we present 2 patients receiving such combination or sequential therapies. Methods: RLT was performed at 6- to 8-wk intervals after the patients either exhausted or were considered unfit for all approved conventional treatments. Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 received RLT sequentially 4 wk after 3 mo of monotherapy with olaparib. Results: Both patients tolerated RLT without any significant hematotoxicity. Patient 2 showed a radiologic and biochemical response, whereas patient 1 achieved prostate-specific antigen stabilization after 3 therapy cycles. Conclusion: These cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be well tolerated in single patients. Visual AbstractKeywords
This publication has 14 references indexed in Scilit:
- 68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancerCancer Imaging, 2019
- Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working groupThe Prostate, 2018
- 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2017
- Radiotherapy and immunotherapy: a beneficial liaison?Nature Reviews Clinical Oncology, 2017
- Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate CancerMolecular Imaging and Biology, 2015
- Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine TumorDiagnostics, 2013
- The role of double-strand break repair — insights from human geneticsNature Reviews Genetics, 2006
- Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediatedInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Partners and pathwaysTrends in Genetics, 2000